H.C. Wainwright views the results from ardiol Therapeutics’ Phase II ARCHER trial of CardiolRx in acute myocarditis as “very supportive” of future development. The safety “was very clean,” further validating the broader CardiolRx and, by extension, CRD-38 development programs, the analyst tells investors in a research note. H.C. Wainwright believes this morning’s data supports its positive view on Cardiol shares and enhances CardiolRx’s attractiveness to a strategic partner. It reiterates a Buy rating on the shares with a $9 price target The company’s current market cap of $112M ascribes no credit for a positive readout in ARCHER, and today’s release “is a positive,” says H.C. Wainwright.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDL:
- Cardiol Therapeutics announces Phase II ARCHER results in myocarditis
- Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis
- Positive Outlook for Cardiol Therapeutics Amid ARCHER Trial Progress and Market Potential
- Cardiol Therapeutics Achieves Database Lock in ARCHER Trial for Acute Myocarditis